^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CART-19
i
Other names: CART-19
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Unicar
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
1year
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1/2, N=15, Recruiting, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Trial completion date: Jan 2024 --> Dec 2025 | Trial primary completion date: Jan 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
CART-19
1year
Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL (ASH 2023)
In this phase 1/2 clinical trial conducted at two centers, we compared the efficacy and safety of ssCART-19 to classical CART-19 cells (cCART-19) in patients with r/r B-ALL (NCT03919240)...Lymphodepletion (fludarabine at 30 mg/m2/day and cyclophosphamide at 300 mg/m2/day) was conducted on days -5, -4, and -3 before infusion... Our clinical studies demonstrated the safety and high efficacy of ssCART-19 with IL-6 gene silencing in patients with relapsed/refractory B-ALL. These findings support the potential of ssCART-19 as a promising therapeutic approach for this challenging patient population.
Clinical • CAR T-Cell Therapy • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
IL6 expression
|
cyclophosphamide • fludarabine IV • CART-19 • ssCART-19
over2years
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1/2, N=15, Recruiting, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2020 --> Jan 2023
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
CART-19
Share via
